Friday, September 18, 2020
Friday, September 18, 2020

DNA Testing Company Teams With Pharmaceutical Giant GlaxoSmithKline
D

Your Content is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published.

When people mail their spit to 23andMe, they are likely thinking mainly about how their genetic material can be used to reveal their personal ancestral history. For years, though, the spit of consenting customers has also been used for scientific research ― profitable scientific research at times.

Now the pharmaceutical giant GlaxoSmithKline has made a $300 million, four-year commitment to support that effort and push it even further into the realm of drug development. The two companies will join forces to design and develop new, more targeted pharmaceuticals.

- Advertisement -

“Since the inception of 23andMe, our mission has been to help people access, understand and benefit from the human genome,” 23andMe founder Anne Wojcicki said Wednesday on her company’s blog.

The first project will delve into potential new Parkinson’s disease treatments.

“By working with GSK, we believe we will accelerate the development of breakthroughs,” Wojcicki said. 23andMe has linked up with other pharma companies, such as Pfizer, in the past for similar purposes.

- Advertisement -

GSK’s chief scientific officer, Hal Barron, said in a statement that he’s particularly excited about the partnership because “we know that drug targets with genetic validation have a significantly higher chance of ultimately demonstrating benefit for patients and becoming medicines.”

Customers are asked when they sign up with 23andMe whether they want to participate in research and can choose to opt out at any time. (Material that has already been sent in and included in a study cannot be withdrawn, however.) The company says most of its 5 million users opt in. On average, their material is used in more than 230 studies on subjects such as Parkinson’s disease or lupus, according to the company’s website.

The point of collaborating with pharmaceutical giants is to give researchers access to a database of genetic and personal information that’s much, much larger than what is typically available. Researchers can then try to identify new links between traits, diseases and genes ― and ideally, use that knowledge to inform therapies.

23andMe pitches customer participation in research as a chance to positively affect health care.

Some, however, see a lot to be concerned about.

Speaking with NBC News, Peter Pitts, president of the Center for Medicine in the Public Interest, suggested 23andMe customers be paid for opting in to the research.

“When two for-profit companies enter into an agreement where the jewel in the crown is your gene sequence and you are actually paying for the privilege of participating, I think that’s upside-down,” Pitts said.

He also questioned the steps 23andMe has taken to ensure customers’ privacy ― a risk the company also flags for customers. If its database were to be hacked, that information could be traced back to individual consumers and used against them.

Story by The Huffington Post.

Protect Independent Journalism

Your Content is a nonprofit newsroom that produces nonpartisan, evidence-based journalism to expose injustice, corruption and wrongdoing.

Spearheading the news revolution for Americans across the nation, Your Content has brought a voice to those the media failed to acknowledge.

This story you’ve just finished was funded by our readers and we hope it inspires you to make a gift to Your Content so that we can publish more reports like this one that holds people in power to account and produces real change.

Your donation will help us ensure that we can continue this critical work. We are busier than ever covering stories you won’t see anywhere else.

Airbnb Files Paperwork for an IPO With Plans to Go Public

Airbnb files confidential paperwork for an IPO, moving ahead with plans to go public.

Dow drops 600 points despite Federal Reserve interest rate cut

US stock futures dropped sharply on Sunday evening with the Dow Jones losing over 600 points despite the Federal Reserve's decision to cut interest rates.

Comcast experiencing ‘national outage’

Xfinity outages have been reported across the United States. The Comcast outage map showing surrounding areas including Philadelphia, Seattle, Houston, and New...

Instagram crashes overnight; sends users flocking to Twitter

Instagram seems to be down for a lot of users worldwide. Instagram’s website and app both are inaccessible at the momentum. People are flocking Twitter...

Snapchat: Ultimate tool for stalkers in 2017

Snapchat unveiled a new feature which allows someone to see the exact location of another user. Literally, if you're in your bedroom - someone knows.

Volvo and Autoliv team up with Nvidia for self-driving cars

Volvo Cars and Swedish car safety supplier Autoliv have signed a deal with U.S. firm Nvidia Corp (NVDA.O), best known for its graphics technology in computer games, to develop software systems for self-driving cars.

Apple debuts HomePod speaker to bring Siri into the living room

Apple on Monday introduced the HomePod speaker to compete with Amazon.com Alexa assistant and Echo devices for users who prefer voice-operated systems.

T-Mobile & expanded network has rivals – and suitors – taking notice

NEW YORK (Reuters) - T-Mobile US Inc (TMUS.O) has built a reputation as a scrappy underdog by offering cell service with no contracts and...

Stay Informed & Get Your Content, Daily.

To be updated with all the latest news, offers and special announcements.

Your Content is a 501(c)(3) non-profit national American media organization of artists and journalists headquartered in Pennsylvania.